TY - JOUR T1 - Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis JF - Anticancer Research JO - Anticancer Res SP - 427 LP - 433 DO - 10.21873/anticanres.13970 VL - 40 IS - 1 AU - LETIZIA GIANONCELLI AU - GIANLUCA SPITALERI AU - ANTONIO PASSARO AU - DAVIDE RADICE AU - CATERINA FUMAGALLI AU - ESTER DEL SIGNORE AU - VALERIA STATI AU - CHIARA MATILDE CATANIA AU - ELENA GUERINI-ROCCO AU - MASSIMO BARBERIS AU - FILIPPO DE MARINIS Y1 - 2020/01/01 UR - http://ar.iiarjournals.org/content/40/1/427.abstract N2 - Background/Aim: The role of anti-PD1/PD-L1 therapy (IO) in NSCLC harboring driver mutations is questionable. This study aimed to examine the efficacy of IO in patients with non-small cell lung cancer (NSCLC) with a KRAS mutation (KRAS+). Patients and Methods: We retrospectively identified NSCLC patients harboring KRAS mutation treated with IO in our Institution. We analyzed the results in comparison to non-KRAS patients. Results: Among 328 consecutive KRAS+ NSCLC patients, 43 (13.1%) received IO in our Institution. In parallel 117 non-KRAS NSCLC patients treated with IO were selected for comparison. The baseline characteristics were similar between the two groups. No significant difference was observed between KRAS+ and non-KRAS patients in terms of mPFS (4.6 vs. 3.3 months, p=0.58) or OS (8.1 vs. 13.0 months, p=0.38). Conclusion: KRAS mutations seem to be irrelevant for selecting patients for IO that could be therefore considered an effective therapy for NSCLC patients, independently of KRAS status. ER -